9 Jefferies Group Cytokinetics Trades
The first Cytokinetics trade was made in Q1 2023. Since then Jefferies Group bought shares three more times and sold shares on five occasions. The investor sold all their shares in Q1 2025 and doesn't own any shares in Cytokinetics anymore.
Avg closing price
Price range
Sold -12.6 Thousand shares
Q1 2025
Avg closing price
$45.99
Price range
$40.19
-
$51.12
New holding (+12.6 Thousand shares)
Q4 2024
Avg closing price
$51.89
Price range
$47.04
-
$58.62
Sold -8.22 Thousand shares
Q3 2024
Avg closing price
$55.74
Price range
$51.22
-
$60.16
Sold 74.3% shares (-23.8 Thousand shares)
Q2 2024
Avg closing price
$60.36
Price range
$47.86
-
$75.05
Increased shares by 27.0% (+6.81 Thousand shares)
Q1 2024
Avg closing price
$77.34
Price range
$63.75
-
$108.06
New holding (+25.2 Thousand shares)
Q4 2023
Avg closing price
$36.21
Price range
$26.88
-
$83.49
Sold -35.6 Thousand shares
Q3 2023
Avg closing price
$33.30
Price range
$29.46
-
$36.61
Sold 11.1% shares (-4.45 Thousand shares)
Q2 2023
Avg closing price
$37.00
Price range
$32.62
-
$40.75
New holding (+40 Thousand shares)
Q1 2023
Avg closing price
$40.80
Price range
$33.36
-
$45.71
News about Cytokinetics Inc and Jefferies Group
Cytokinetics (NASDAQ:CYTK) Earns Buy Rating from JMP Securities
JMP Securities reaffirmed their buy rating on shares of Cytokinetics (NASDAQ:CYTK) in a research report sent to investors on Thursday, Price Targets.com repo...
Vanguard Group Inc. Cuts Holdings in Cytokinetics, Incorporated (NASDAQ:CYTK)
Vanguard Group Inc. trimmed its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 3.5% in the second quarter, according to the company in its...